疼痛医学医师在Medicare Part D项目中的阿片类药物处方:一项横断面研究
阿片类药物、抗惊厥药和加巴喷丁类药物索赔数和费用最高;品牌阿片类药物索赔占比小(8%)但费用高于仿制药。PMP开具的阿片类药物处方仅占全部阿片类药物索赔的12%,费用前5%的PMP处方索赔数是平均PMP的10倍。
要点
- PMP处方仅占Part D药物支出的0.4%,阿片类药物是PMP最常见的处方药物类别。
- 品牌阿片类药物仅占阿片类药物索赔的8%,但相关费用高于仿制药。
- 费用前5%的PMP处方索赔数是平均PMP的10倍,且品牌药比例和供应天数更高。
核心结论
- 阿片类药物是PMP在Medicare Part D中开具的最常见药物,但PMP开具的阿片类药物处方仅占全部阿片类药物索赔的12%。
- 费用前5%的PMP处方索赔数是平均PMP的10倍。
研究设计与样本
- 横断面研究,数据来源于CMS慢性病数据仓库的Medicare Part D处方药物事件记录,仅纳入疼痛管理和介入疼痛管理分类的提供者,分析限于索赔数>250的药物。
主要发现
- 阿片类药物、抗惊厥药和加巴喷丁类药物在PMP处方中索赔数和费用最高。
- 品牌阿片类药物仅占阿片类药物索赔的8%,但费用高于仿制药。
- 费用前5%的PMP处方索赔数更多、品牌药比例更高、供应天数更长。
- PMP费用前10的药物列表中有多种阿片类药物。
临床怎么用
- 关注PMP阿片类药物处方中的品牌药使用和长供应天数模式,尤其是高费用处方者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pain medicine physicians (PMP) are a group of physicians with background training in various primary specialties with interest and expertise in managing chronic pain disorders. Our objective is to analyze prescription drug (PD) claims from the Medicare Part D program associated with PMP to gain insights into patterns, associated costs, and potential cost savings areas. METHODS: The primary data source for Part D claims data is the Centers for Medicare and Medicaid Services (CMS) Chronic Conditions Data Warehouse, which contains Medicare Part D prescription drug events (PDE) records received through the claims submission cutoff date. Only providers with taxonomies of pain management (PM) and interventional pain management (IPM) were included in the study. The analysis of PDE was restricted to drugs with >250 claims. The distribution of claims and costs were analyzed based on drug class and provider specialty. Subsequently, we explored claims and expenses for opioid drug prescriptions in detail. Prescribing characteristics of the top 5% of providers by costs and claims were examined to gain additional insights. The costs and claims were explored for the top 10 drugs prescribed by PMP in 2017. RESULTS: There were a total of unique 3280 PMP-prescribed drugs with an associated expense of 652 million dollars in the 2017 Medicare Part D program. Prescriptions related to PMP account for a tiny fraction of the program's drug expenditure (0.4%). Opioids, anticonvulsants, and gabapentinoids were associated with the largest number of claims and the largest expenses within this fraction. Among opioid drug prescriptions, brand-named drugs account for a small fraction of claims (8%) compared to generic drugs. However, the expenses associated with brand name drugs were higher than generic drugs. Prescribers in the top 5% by PD costs had a higher number of claims, prescribed a higher proportion of branded medications, and had prescriptions associated with longer day supply compared to an average PMP. There were several opioid medications in the top 10 PD list by cost associated with PMP. CONCLUSIONS: Opioids were the most common medications among Medicare part D claims prescribed by PMP. Only 12% of the total opioid PD claims were by PMP. The top 5% of PMP prescribers had 10 times more claims than the average PMP.
引用
- Goel V, Moran B, Kaizer AM, et al. Opioid Prescriptions by Pain Medicine Physicians in the Medicare Part D Program: A Cross-Sectional Study. Anesth Analg. 2021. PMID: 33591120. doi:10.1213/ANE.0000000000005399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。